-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Intellia Therapeutics, Raises Price Target to $25

Benzinga·01/28/2026 17:15:14
Listen to the news
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and raises the price target from $15 to $25.